143 related articles for article (PubMed ID: 28398333)
21. Serelaxin for the treatment of acute heart failure: a review with a focus on end-organ protection.
Díez J; Ruilope LM
Eur Heart J Cardiovasc Pharmacother; 2016 Apr; 2(2):119-30. PubMed ID: 27418970
[TBL] [Abstract][Full Text] [Related]
22. Novel Therapies for Heart Failure - Where Do They Stand?
Greenberg B
Circ J; 2016 Aug; 80(9):1882-91. PubMed ID: 27545139
[TBL] [Abstract][Full Text] [Related]
23. Serelaxin and acute heart failure.
Tietjens J; Teerlink JR
Heart; 2016 Jan; 102(2):95-9. PubMed ID: 26603680
[TBL] [Abstract][Full Text] [Related]
24. Emerging role of serelaxin in the therapeutic armamentarium for heart failure.
Varr BC; Maurer MS
Curr Atheroscler Rep; 2014 Oct; 16(10):447. PubMed ID: 25108571
[TBL] [Abstract][Full Text] [Related]
25. Recombinant human H2 relaxin (serelaxin) as a cardiovascular drug: aiming at the right target.
Bani D
Drug Discov Today; 2020 Jul; 25(7):1239-1244. PubMed ID: 32360533
[TBL] [Abstract][Full Text] [Related]
26. Recent Progress in the Therapeutic Role of Serelaxin in Vascular Dysfunction.
Murtaza G; Siddiqui A; Hussain I
Curr Protein Pept Sci; 2018; 19(11):1079-1087. PubMed ID: 29984650
[TBL] [Abstract][Full Text] [Related]
27. Serelaxin, recombinant human relaxin-2, for heart failure patients: A systematic review and meta-analysis.
Yu L; Cao L; Sun J; Li Z; Yao F; Zhou Y
Medicine (Baltimore); 2018 Jun; 97(25):e11010. PubMed ID: 29923986
[TBL] [Abstract][Full Text] [Related]
28. [The RELAX-AHF study].
Mortara A
G Ital Cardiol (Rome); 2015 Apr; 16(4):193-7. PubMed ID: 25959752
[No Abstract] [Full Text] [Related]
29. Representativeness of RELAX-AHF clinical trial population in acute heart failure.
Wang TS; Hellkamp AS; Patel CB; Ezekowitz JA; Fonarow GC; Hernandez AF
Circ Cardiovasc Qual Outcomes; 2014 Mar; 7(2):259-68. PubMed ID: 24594552
[TBL] [Abstract][Full Text] [Related]
30. Effect of serelaxin on mode of death in acute heart failure: results from the RELAX-AHF study.
Felker GM; Teerlink JR; Butler J; Hernandez AF; Miller AB; Cotter G; Davison BA; Filippatos G; Greenberg BH; Ponikowski P; Voors AA; Hua TA; Severin TM; Unemori E; Metra M
J Am Coll Cardiol; 2014 Oct; 64(15):1591-8. PubMed ID: 25301463
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics of serelaxin in patients with severe renal impairment or end-stage renal disease requiring hemodialysis: A single-dose, open-label, parallel-group study.
Dahlke M; Halabi A; Canadi J; Tsubouchi C; Machineni S; Pang Y
J Clin Pharmacol; 2016 Apr; 56(4):474-83. PubMed ID: 26239266
[TBL] [Abstract][Full Text] [Related]
32. Relaxin/serelaxin for cardiac dysfunction and heart failure in hypertension.
Chunduri P; Patel SA; Levick SP
Adv Pharmacol; 2022; 94():183-211. PubMed ID: 35659372
[TBL] [Abstract][Full Text] [Related]
33. RELAX-AHF: rising from the doldrums in acute heart failure.
Konstam MA
Lancet; 2013 Jan; 381(9860):5-6. PubMed ID: 23141815
[No Abstract] [Full Text] [Related]
34. Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes.
Metra M; Cotter G; Davison BA; Felker GM; Filippatos G; Greenberg BH; Ponikowski P; Unemori E; Voors AA; Adams KF; Dorobantu MI; Grinfeld L; Jondeau G; Marmor A; Masip J; Pang PS; Werdan K; Prescott MF; Edwards C; Teichman SL; Trapani A; Bush CA; Saini R; Schumacher C; Severin T; Teerlink JR;
J Am Coll Cardiol; 2013 Jan; 61(2):196-206. PubMed ID: 23273292
[TBL] [Abstract][Full Text] [Related]
35. Serelaxin for the treatment of heart failure.
Moin DS; Bloom MW; Papadimitriou L; Butler J
Expert Rev Cardiovasc Ther; 2016 Jun; 14(6):667-75. PubMed ID: 27045761
[TBL] [Abstract][Full Text] [Related]
36. Design and Synthesis of Potent, Long-Acting Lipidated Relaxin-2 Analogs.
Muppidi A; Lee SJ; Hsu CH; Zou H; Lee C; Pflimlin E; Mahankali M; Yang P; Chao E; Ahmad I; Crameri A; Wang D; Woods A; Shen W
Bioconjug Chem; 2019 Jan; 30(1):83-89. PubMed ID: 30543420
[TBL] [Abstract][Full Text] [Related]
37. Relaxin: a novel agent for the treatment of acute heart failure.
Wilson SS; Ayaz SI; Levy PD
Pharmacotherapy; 2015 Mar; 35(3):315-27. PubMed ID: 25759289
[TBL] [Abstract][Full Text] [Related]
38. Relaxin' the Heart: A Novel Therapeutic Modality.
Raleigh JM; Toldo S; Das A; Abbate A; Salloum FN
J Cardiovasc Pharmacol Ther; 2016 Jul; 21(4):353-62. PubMed ID: 26589290
[TBL] [Abstract][Full Text] [Related]
39. Recombinant human relaxin-2: (how) can a pregnancy hormone save lives in acute heart failure?
Dschietzig TB
Am J Cardiovasc Drugs; 2014 Oct; 14(5):343-55. PubMed ID: 24934696
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics of serelaxin in patients with hepatic impairment: a single-dose, open-label, parallel group study.
Kobalava Z; Villevalde S; Kotovskaya Y; Hinrichsen H; Petersen-Sylla M; Zaehringer A; Pang Y; Rajman I; Canadi J; Dahlke M; Lloyd P; Halabi A
Br J Clin Pharmacol; 2015 Jun; 79(6):937-45. PubMed ID: 25511105
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
